Dr. Robyn Tamblyn is a Professor in the Department of Medicine and the Department of Epidemiology and Biostatistics at McGill University. She is a James McGill Chair, a Medical Scientist at the McGill University Health Center Research Institute, and the Scientific Director of the Clinical and Health Informatics Research Group at McGill University. Dr Tamblyn's ground-breaking research on educational outcomes has elucidated important relationships between health professional training, licensure and practice that have subsequently guided credentialing policies. Her work on prescription drug use, its determinants, and computerized interventions to improve drug safety (MOXXI) have been recognized internationally. She leads a CIHR-funded team to investigate the use of e-health technologies to support integrated care for chronic disease, and co-leads a Canadian Foundation for Innovation Informatics Laboratory to create advanced technologies to monitor adverse events in populations and create new tools to improve the safety and effectiveness of health care. Her work is published in the Journal of the American Medical Association, the Annals of Internal Medicine, the British Medical Journal, Medical Care, and Health Services Research among others. She has been awarded the CHSRF KT award for her research in improving the use of medication as well as the ACFAS Bombardier award for innovation in the development of a computerized drug management system.
P7: Genome Canada GPS Series: Personalized Medicine and Health Care Policy
As part of Genome Canada’s 2012-2013 GPS Series "Where Genomics, Public Policy and Society Meet," the session will facilitate a dialogue between researchers, policy-makers and other stakeholders interested in GE3LS (Genomics and its Ethical, Economic, Environmental, Legal, and Social aspects), health policy and genomic-based medicine. The session will focus on the presentation of a draft policy brief and invited commentaries.
Titled “Personalised Medicine and Healthcare Policy: from Science to Value,” the draft brief will consider how personalized medicine interventions can be defined as interventions that rely on genetic, proteomic, and metabolic characteristics of an individual, or condition to identify the most effective or efficient clinical management strategy. It also describes how developments in the range and performance of diagnostic technologies, along with advances in laboratory information technology, industry activity, consumer awareness, the imperative to manage health care expenditure, and the need for effective care for complex disease are all driving societal and patient expectations. In light of these considerations, the brief notes that effective development and commercialization will require coordination across science, industry and payer communities. All stakeholders will need to fully understand and identify the societal value associated with research and commercialization to make the most of investment and realize the full potential of these interventions for patients, whilst ensuring they do not drive out existing high value healthcare activities.
Overall, this session will explore needed steps in research, development and regulation to facilitate the translation and adoption of high value personalized medicine in the Canadian health care system. It will examine best approaches and policy options to evaluate interventions and provide early identification of high value personalized medicine candidates, likely to contribute to the health and wealth of Canadians.
Jim Pelot is serial entrepreneur and co-owner of ArcticDx Inc, a diagnostic company commercializing genetic discoveries. Arctic launched a genetic test for Age-related Macular Degeneration, the leading cause of blindness for those over 55 in the Western World. Jim is CFO and COO of Arctic. Prior to Arctic, Jim was CFO and COO of Tm Bioscience, a publically listed genetic test development Company headquartered in Toronto.
Chris McCabe has worked on methodological and applied research for evaluating new technologies to inform health reimbursement decisions for the last 20 years, primarily in the United Kingdom, but also working for governments in Europe, North America and Australasia. He was co-author of the 2004 edition of the UK National Institute for Health and Clinical Excellence (NICE) Guide to the Methods of Health Technology Assessment, and an expert advisor to its update in 2008. With others, he has made key contributions to the application of Decision Analytic Modelling and Value of Information methods to health care resource allocation decisions.
Chris McCabe was founding Director of the NICE Decision Support Unit, an academic collaboration of 4 Universities providing methodological support and expert peer review to the NICE Technology Appraisal programme. He also was first author on one of the early papers to argue that regulatory authorities needed to consider cost effectiveness in order to incentivise manufacturers to design R&D processes to develop cost effective new technologies.
Prior to moving to the University of Alberta, he was the EPSRC Translational Research Professor in Health Economics at the University of Leeds, in the UK, as well as a founder member of the NICE Medical Technology Advisory Committee, which appraises non-drug technologies including biomarkers for the UK National Health Service. He currently is senior health economist and Co-Investigator on two UK NIHR funded biomarkers trials, and PI of the Genome Canada funded project “PACE-Omics: Personalized, Accessible, Cost-Effective Applications of ‘Omics’ Technologies”.
Don Husereau is a Senior Associate with the Institute of Health Economics. He is also an Adjunct Professor of Medicine at The University of Ottawa and Senior Scientist at the University for Health Sciences, Medical Informatics and Technology in Hall in Tirol, Austria. He is a former Director of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) and was a Director and Senior Advisor for the Canadian Agency for Drugs and Technologies in Health (CADTH). He is also an Editorial Advisor for Value in Health. From 2006-2009, he was Chair of the health technology assessment exchange, a network of Canadian HTA producers. He has recently examined processes for incorporating value assessments into pricing and procurement decisions and larger health technology policy frameworks.
As Genome Canada’s Director, National GE3LS Program, Karine Morin oversees activities related to the ethical, economic, environmental, legal and social (GE3LS) aspects of genomics research.
Prior to joining Genome Canada, Karine was a Senior Ethics Policy Advisor at the Canadian Institutes of Health Research (CIHR). She also conducted GE3LS research at the University of Ottawa’s Institute of Science, Society and Policy.
She worked for several years in the US, including as the Director of Ethics Policy at the American Medical Association. Before leaving Canada, she worked for the Commission of Inquiry on the Blood System in Canada (Krever Commission).
She holds a Masters in Law (LLM) from the University of Pennsylvania and is a graduate of McGill University School of Law, where she obtained a joint degree in civil (B.C.L.) and common law (LL.B).
Over the years, she has published widely in bioethics and law, and has taught as an adjunct at several universities in the US and Canada.